Citigroup Inc Viracta Therapeutics, Inc. Transaction History

Citigroup Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	SELL	$1.26 - $4.38 $570 - $1,984	-453 Reduced 82.21%	98 $0
Q3 2022 Nov 10, 2022	SELL	$3.32 - $5.69 $1,643 - $2,816	-495 Reduced 47.32%	551 $2,000
Q2 2022 Aug 10, 2022	SELL	$1.87 - $5.0 $2,444 - $6,535	-1,307 Reduced 55.55%	1,046 $4,000
Q1 2022 May 12, 2022	SELL	$2.23 - $4.76 $17,358 - $37,051	-7,784 Reduced 76.79%	2,353 $11,000
Q4 2021 Feb 10, 2022	BUY	$3.37 - $7.91 $19,987 - $46,914	5,931 Added 141.01%	10,137 $37,000
Q3 2021 Nov 10, 2021	BUY	$7.84 - $12.53 $32,975 - $52,701	4,206 New	4,206 $34,000

5.63M

Ticker VIRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,558,200
Market Cap $9.39M
Description
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.